Madrigal Books Its First Profit Into a 29% Drawdown

Rezdiffra cleared $1B year-to-date and the P&L flipped positive — while the stock sits well below its December peak and management quietly escalates a cirrhosis land grab the tape isn't paying for yet.

MDGL · Earnings Call · 2026-11-03

The P&L turns, and management immediately walks it back

For eleven quarters Madrigal has been a pure top-line story. That ended on November 3. Revenue of $431.3 million (up 50% year over year), $1.1 billion year-to-date, and — the number that actually mattered — net income of $55.4 million versus a $114.2 million loss a year ago. “The third quarter marked another important milestone for Madrigal, our first quarter of profitability.” — Mardi Dier, Chief Financial Officer · 2026-11-03 What is instructive is how fast the company disowned it. Within the same breath, Mardi Dier framed profitability as incidental: “We remain a top-line growth story and may dip in and out of profitability in the near term based on the timing of investments.” — Mardi Dier, Chief Financial Officer · 2026-11-03 That is not evasion so much as positioning — the company wants to be valued on the revenue line, and it is spending accordingly: SG&A of $265.7 million in the quarter, with Q4 guided higher, plus three phase II combination trials slated for 2027. The scale of the operating leverage now visible is real, though. Quarterly net income swung from -$58 million in Q2 to +$55 million, and effective net cash rebuilt from a $339 million trough to $961.8 million — two consecutive quarters of positive operating cash flow, self-funding the pipeline. That is the quiet headline: Madrigal no longer needs the capital markets to fight this war.

The land grab moves to cirrhosis

The strategic news is bigger than the P&L. Two things happened to the F4c program this quarter. First, the addressable market estimate for F4c was raised to 360,000 U.S. patients, up more than 45% from the 245,000 previously shared — Bill Sibold's framing was pointed: “That is larger than the F2, F3 patient population when we launched Rezdiffra. Expanding into F4c could double Rezdiffra's opportunity.” — Bill Sibold, Chief Executive Officer · 2026-11-03 Second, and more consequential, the company added a second outcomes trial: MAESTRO-CSPH, a 2,000-plus patient study enriched for clinically significant portal hypertension, to start in the first half of 2027, alongside the ongoing 845-patient MAESTRO NASH OUTCOMES. Roughly 3,000 patients across the two. This is a keyword that is genuinely new for the company — it debuted this quarter at the top of Madrigal's own theme ranking — and it is a strategic escalation, not a routine trial update. Why spend into a second mega-trial before the first one reads out?

A lot of companies would wait and start a trial after approval and ultimately find themselves in a bit of a data desert, and they are playing continuous catch-up. That is not what you do as the leader in the space. We don't want to have any daylight between our approval and ultimately, if any other company is successful to get there.
Bill Sibold, Chief Executive Officer · 2026-11-03

The competitive backdrop justifies the paranoia: management now says the earliest potential F4c entrant has slipped to 2030, giving Madrigal what Sibold calls a 15-quarter lead. The Mega blockbuster language is back for a third straight quarter — but this time it is backed by a doubling of the cirrhosis denominator rather than the F2/F3 base.

What has not changed — the GLP-1 shrug, and the gross-to-net clock

The most repeated sentence in Madrigal's Q&A history is that GLP-1s do not hurt. It appeared again verbatim in substance: “It has not really dented us, our growth in any way, having the GLP-1 Wegovy approved on the market.” — Bill Sibold, Chief Executive Officer · 2026-11-03 This is now the fifth consecutive quarter of that reassurance — in November 2025 it was “this is the first quarter where we've had Novo in the market” — William Sibold, Chief Executive Officer · 2025-11-04, and by May 2026, “Wegovy is being used, but certainly not to the detriment of Rezdiffra.” — William Sibold, Chief Executive Officer · 2026-05-06 Repetition does not make it wrong — patients keep coming (patients on therapy nearly doubled year over year to over 55,850) and roughly a quarter sit on a background therapy GLP-1 — but it has become boilerplate, and boilerplate eventually gets tested. The fresher thread is pricing. Gross-to-net has travelled from a 20%–30% range in 2025, to the high-30s in 2026, to a 2027 guide of "plus or minus the high end." Bill has said for a year that “gross to net only goes in one direction” — William Sibold, Chief Executive Officer · 2025-11-04, and he is being proved right — the new wrinkle is Medicare Part D contracting now being negotiated for a 2027 start. It is the single most important unpriced variable in the model, and the company will not quantify it. On the trial that matters most, precision improved but transparency did not. The event rate readout was narrowed from "2027" to "late 2027" — real progress — yet David Soergel declined to disclose blinded accrual: “We're not providing really specifics around event accrual because these more modest-sized trials, it tends to be a bit choppy.” — Dave Soergel, Chief Medical Officer · 2026-11-03 Analysts pressed, twice, on whether 5%–10% placebo event rates are credible against controlled studies showing 2%–3%. There was no new answer; there never is until the data arrives.

The tape and the fundamentals have divorced

Here is the tension worth owning. Fundamentally, this was Madrigal's best quarter ever. In the market, the stock is down 16.1% over 90 days, sits 23.8% below its July 8 peak of $565.40, and 28.5% under the December 2025 high of $602.83. The price-to-revenue multiple has compressed from a 407.9x peak to 9.7x. Some of that is arithmetic — revenue went from near-zero to a $1.7 billion annualized run rate. But some of it is a genuine change in how the market pays for Madrigal: not for optionality, for execution. There is a rotation context too. Over the last 30 days the global tape's losers are clustered in AI-infrastructure and bitcoin-mining themes, while the 90-day biotech gainers include clinical-catalyst names tied to early stage cancers, Pulsed Field Ablation and small cell lung cancer. Capital is hunting catalysts. Madrigal's problem is that its next binary catalyst — MAESTRO NASH OUTCOMES — is more than a year away, and the intervening quarters are, by management's own admission, about "steadily adding patients" and absorbing Medicare rebates. That is the story. A company that just proved its commercial engine and its P&L works, told the market it will be judged on a cirrhosis trial in late 2027 — and the market, for now, is discounting the wait. The catalyst is real; the patience is not free.